# Regulatory T Cells Boost Efficacy of Post-Infarction Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cell Transplants

**Authors:** Aline Derisio de Lima, Hernán Gonzalez-King Garibotti, Qing-Dong Wang, Cecilia Graneli, Tania Incitti, Valérie Bellamy, Maria Eduarda Anastácio Borges Corrêa, Myriam Assal, Makoto Miyara, Jean-Sébastien Silvestre, Karin Jennbacken, Philippe Menasché

PMC · DOI: 10.3390/cells14130956 · Cells · 2025-06-23

## TL;DR

Regulatory T cells help improve heart function after stem cell transplants by reducing harmful immune responses and promoting healing.

## Contribution

This study shows that Treg therapy enhances CPC transplant outcomes by modulating immune responses and improving cardiac function.

## Key findings

- Treg therapy with CPCs improved left ventricular systolic function and reduced myocardial fibrosis.
- Tregs decreased pro-inflammatory cytokines and NK cell populations in cardiac tissue.
- Treg therapy induced systemic immune modulation without directly preventing graft rejection.

## Abstract

Cell therapy is promising for heart failure treatment, with growing interest in cardiovascular progenitor cells (CPCs) from pluripotent stem cells. A major challenge is managing the immune response, due to their allogeneic source. Regulatory T cells (Treg) offer an alternative to pharmacological immunosuppression by inducing immune tolerance. This study assesses whether Treg therapy can mitigate the xeno-immune response, improving cardiac outcomes in a mouse model of human CPC intramyocardial transplantation. CPCs stimulated immune responses in allogeneic and xenogeneic settings, causing proliferation in T cell subsets. Tregs showed immunosuppressive effects on T lymphocyte populations when co-cultured with CPCs. Post infarction, CPCs were transplanted intramyocardially into an immune-competent mouse model 3 weeks after myocardial infarction. Human or murine Tregs were intravenously administered on transplantation day and three days later. Control groups received CPCs without Tregs or saline (PBS). CPCs with Tregs improved LV systolic function in three weeks, linked to reduced myocardial fibrosis and enhanced angiogenesis. This was accompanied by decreased splenocyte NK cell populations and pro-inflammatory cytokine levels in cardiac tissue. Treg therapy with CPC transplantation enhances cardiac functional and structural outcomes in mice. Though it does not directly avert graft rejection, it primarily affects NKG2D+ cytotoxic cells, indicating systemic immune modulation and remote heart repair benefits.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), myocardial infarction (MONDO:0005068)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Klrk1 (killer cell lectin-like receptor subfamily K, member 1) [NCBI Gene 27007] {aka D6H12S2489E, NKG2-D, Nkg2d}
- **Diseases:** myocardial infarction (MESH:D009203), inflammatory (MESH:D007249), heart failure (MESH:D006333), Infarction (MESH:D007238), myocardial fibrosis (MESH:D005355)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12248464/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12248464/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12248464/full.md

---
Source: https://tomesphere.com/paper/PMC12248464